1. Inicio
  2. Publicaciones
  3. Predictors of poor prognosis in a large cohort of patients with hereditary cardiac transthyretin amyloidosis.

Predictors of poor prognosis in a large cohort of patients with hereditary cardiac transthyretin amyloidosis.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Ripoll-Vera T
  • de Frutos F
  • González-Costello J
  • Manovel-Sánchez AJ
  • Bosch-Rovira MT
  • García-Pinilla JM
  • Robledo-Iñarritu M
  • Limeres-Freire J
  • García-Álvarez A
  • Gallego-Delgado M
  • Espinosa-Castro MÁ
  • López-Aguilera J
  • Macías-Ruiz R
  • Valverde-Gómez M
  • Arana-Achaga X
  • Rodríguez-Serrano AI
  • Alania-Torres E
  • Urbano-Moral JÁ
  • Larrañaga-Moreira JM
  • Tirón C
  • Restrepo-Córdoba MA
  • Lozano-Bahamonde A
  • Ruiz-Guerrero L
  • Revilla-Martí P
  • Onaindia-Gandarias JJ
  • Camacho-Jurado FJ
  • Peña-Peña ML
  • Cordero-Pereda D
  • Hernández-Baldomero IF
  • García-Granja PE
  • Ruiz-Bustillo S
  • Álvarez-Rubio J

Grupos

Abstract

INTRODUCTION AND OBJECTIVES: Hereditary transthyretin amyloidosis (hATTR) is a rare, multisystemic, autosomal dominant disease. Cardiac involvement worsens prognosis. We aimed to characterize Spanish patients with hATTR cardiac amyloidosis (hATTR-CA) and to identify predictors of poor prognosis. METHODS: We conducted a retrospective, multicenter study in 39 Spanish hospitals, including adults with genetically confirmed hATTR and cardiac involvement (January 2000-September 2022). Independent predictors of poor prognosis (death, heart transplantation, heart failure, or cardiovascular hospitalization) were identified using multivariate logistic regression. Data were also collected on clinical and genetic characteristics, management patterns, and event-free survival. RESULTS: A total of 442 patients were included (67.6% male; median age at diagnosis, 65 years). Fifteen TTR variants were identified, with p.Val30Met being the most frequent (64.9%). The most common extracardiac manifestation was neuropathy (64.6%). At baseline, most patients were in New York Heart Association class I-II, with progressive worsening during follow-up. Overall, 48.9% of patients were hospitalized, and 21.9% died; 25.3% of deaths were heart failure-related. Five-year event-free survival was 80.2% from symptom onset and 66.9% from diagnosis. Disease-specific treatments (tafamidis, patisiran, inotersen, or liver transplant) were associated with improved survival (P <.001). In an exploratory analysis stratified by diagnosis before vs after 2018, event-free survival did not differ significantly (HR, 1.04; 95%CI, 0.63-1.72; P=.88). Independent predictors of poor prognosis included New York Heart Association class II-IV, lower left ventricular ejection fraction, elevated N-terminal pro-B-type natriuretic peptide, and the presence of neurological involvement. CONCLUSIONS: This national cohort-the largest reported to date-highlights the clinical and genetic heterogeneity of hATTR -CA in Spain. Early diagnosis and disease-specific therapies are essential to improving prognosis.

Copyright © 2025 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
1885-5857, 1885-5857

REVISTA ESPANOLA DE CARDIOLOGIA  EDICIONES DOYMA S A

Tipo:
Article
Páginas:
618-630
PubMed:
41448563
Factor de Impacto:
0,385 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Amiloidosis hereditaria; Cardiomyopathy; Heart Failure; Hereditary amyloidosis; Insuficiencia cardiaca; Miocardiopatia; Polineuropatía; Polyneuropathy; Transthyretin; Transtirretina

Compartir